Victory Pharma Announces Launch of Additional Naprelan(R) Prescription Products
specialty pharmaceutical company, today announced that it is launching two
additional dosage strengths of Naprelan(R) (naproxen sodium)
Controlled-Release Tablets. NAPRELAN is a once-daily, controlled-release
formulation of naproxen sodium, a non-steroidal anti-inflammatory drug (NSAID)
indicated for the treatment of a number of conditions, including
osteoarthritis, rheumatoid arthritis and management of mild to moderate pain.
Victory’s promotional efforts will be directed primarily at pain management
specialists, rheumatologists, orthopedic surgeons and selected primary care
NAPRELAN. Victory plans to commence promotion on 500 milligram and 750
milligram Naprelan dose strengths by
additional strengths of NAPRELAN, we will further leverage our commercial
organization and provide the dosing flexibility sought by physicians treating
pain and inflammation with NSAIDs,” said
Executive Officer of Victory Pharma, Inc.
“An important factor in our decision to acquire the U.S. marketing rights
to NAPRELAN in late 2006 was the opportunity to offer a differentiated pain
therapy in light of the market withdrawal of certain COX-2 inhibitor drugs,”
Mr. Heck further stated. “We believe NAPRELAN is an attractive option for
pain management. Its active ingredient, naproxen sodium, has a well
established efficacy and safety profile, and its patented, controlled release
technology provides patients with the convenience of once-daily dosing.”
NAPRELAN (naproxen sodium) Controlled-Release Tablets are commercially
available in 375 milligram, 500 milligram and 750 milligram dosage strengths.
NAPRELAN 750 milligram is the only 750 milligram strength naproxen / naproxen
sodium available in the US market.
NAPRELAN Tablets use Elan’s proprietary Intestinal Protective Drug
Absorption System (IPDAS(R)) Technology. This delivery system combines an
immediate release component with a sustained release component of
microparticles that are widely dispersed, allowing absorption of the active
ingredient throughout the gastrointestinal tract and providing convenient
NAPRELAN Tablets are indicated for the treatment of rheumatoid arthritis,
osteoarthritis, ankylosing spondylitis, tendinitis, bursitis and acute gout.
It is also indicated for the relief of mild to moderate pain and the treatment
of primary dysmenorrhea.
Important Safety Information
NAPRELAN Tablets are contraindicated in patients with known
hypersensitivity to naproxen or naproxen sodium.
NAPRELAN Tablets should not be given to patients who have experienced
asthma, urticaria, or allergic-type reactions after taking aspirin or other
non-steroidal anti-inflammatory drugs (NSAIDs). Severe, rarely fatal,
anaphylactic-like reactions to NSAIDs have been reported in such patients.
Please see full prescribing information including BOXED warning regarding
cardiovascular and gastrointestinal risks.
Full prescribing information for NAPRELAN Tablets may be obtained in the
U.S. from Victory Pharma Professional Services by calling toll free
866-427-6819 or on Victory Pharma’s Web site at http://www.victorypharma.com.
About Victory Pharma
Founded in 2003, Victory Pharma, Inc. is a privately held specialty
pharmaceutical company headquartered in
acquiring, developing and marketing products to treat pain and related
conditions. Victory markets NAPRELAN and other pain products to pain
management specialists, rheumatologists, orthopedic surgeons and selected
primary care physicians through its physician office-based field sales force.
Victory is also developing proprietary products for the treatment of chronic
pain and common, opiate-induced side effects. Further information regarding
Victory Pharma is available at http://www.victorypharma.com.
NAPRELAN(R) is a trademark of Elan Corporation, plc. IPDAS(R) is a
trademark of Elan Pharma Int. Ltd.
SOURCE Victory Pharma, Inc.